Other News

Colibri Heart Valve to Present One-Year Patient Follow-Up Results from Clinical Feasibility Study of Second-Generation TAVI System at EuroPCR

BROOMFIELD, CO , May 14, 2019 (GLOBE NEWSWIRE) — Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that results from the company’s international, single-arm, open-label early feasibility study (EFS) of the Colibri transcatheter aortic valve implantation (TAVI) system will be presented at the upcoming EuroPCR annual […]

Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

VANCOUVER, May 14, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has entered into an agreement to sell to […]

John Fletcher Named Strategic Advisor to Micro Medical Solutions

WILMINGTON, Mass., May 14, 2019 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, announced today that John Fletcher has signed on as a strategic advisor to the company’s senior management. Mr. Fletcher is the founder and leader of healthcare consulting and […]

FDA grants clearance for a heart murmur detection solution on a personal mobile device

eMurmur ID is an artificial intelligence-based solution that enables healthcare providers to detect and classify heart murmurs with expert-level accuracy OTTAWA, May 14, 2019 /PRNewswire/ – eMurmur® today announced that its flagship “eMurmur ID” solution has received FDA clearance, enabling a new era in heart murmur detection. eMurmur ID is a mobile and cloud […]

Cordis Continues to Expand Interventional Cardiology Portfolio with Radial Offering

DUBLIN, Ohio, May 14, 2019 /PRNewswire/ — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses the radial artery in the wrist to access the body’s […]

Eximo Medical Ltd. Announces the First Successful Use of the B-Laser™ Atherectomy System in Crossing Chronic Total Occlusion (CTO) without a guidewire

REHOVOT, Israel–(BUSINESS WIRE)–Eximo Medical Ltd., announced today the first successful use of the B-Laser™Atherectomy System in a “step-by-step” approach (crossing a non-crossable CTO cap without guidewire) for the therapy of patients afflicted by highly complex, arterial occlusive peripheral arterial disease (PAD) as well as the first ever utilization of On-line Photo-Acoustic Monitoring […]

Ra Medical Systems Reports First Quarter 2019 Financial Results

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2019 and provides a business update. Recent Operational Highlights Submitted an Investigational Device Exemption (IDE) to the […]

Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under […]

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days. The Impella 5.0 and the Impella LD are forward flow heart pumps […]